NASDAQ:ARGX - argenx Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$101.96 -1.33 (-1.29 %)
(As of 12/14/2018 04:00 PM ET)
Previous Close$101.96
Today's Range$100.42 - $102.89
52-Week Range$53.93 - $111.43
Volume131,206 shs
Average Volume251,912 shs
Market Capitalization$3.32 billion
P/E Ratio-72.83
Dividend YieldN/A
Beta1.67
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

Receive ARGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARGX
Previous Symbol
CUSIPN/A
Phone329-310-3400

Debt

Debt-to-Equity RatioN/A
Current Ratio13.16
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-72.83
Forward P/E Ratio-54.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$44.74 million
Price / Sales73.31
Cash FlowN/A
Price / Cash FlowN/A
Book Value$12.12 per share
Price / Book8.41

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees73
Outstanding Shares32,170,000
Market Cap$3.32 billion
OptionableOptionable

argenx (NASDAQ:ARGX) Frequently Asked Questions

What is argenx's stock symbol?

argenx trades on the NASDAQ under the ticker symbol "ARGX."

What price target have analysts set for ARGX?

9 Wall Street analysts have issued twelve-month price targets for argenx's shares. Their forecasts range from $110.00 to $161.00. On average, they expect argenx's stock price to reach $140.5714 in the next year. This suggests a possible upside of 37.9% from the stock's current price. View Analyst Price Targets for argenx.

What is the consensus analysts' recommendation for argenx?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for argenx.

What are Wall Street analysts saying about argenx stock?

Here are some recent quotes from research analysts about argenx stock:
  • 1. According to Zacks Investment Research, "argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. " (12/12/2018)
  • 2. Stifel Nicolaus analysts commented, "We continue to remain positive on the stock at these levels and reiterate our Buy rating. Key Points The AML development landscape is crowded but ARGX-110 stands alone as the only program targeting CD70. Given the poor outcomes in the elderly and high relapse rates in AML, there are many broad and targeted treatments (i.e., specific mutations, immunotherapies) currently in development. KOLs we spoke with indicated there is no silver bullet" when treating the disease and there certainly seems room for new treatments." (10/16/2018)

Has argenx been receiving favorable news coverage?

Media headlines about ARGX stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. argenx earned a news sentiment score of 1.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future.

Who are some of argenx's key competitors?

Who are argenx's key executives?

argenx's management team includes the folowing people:
  • Mr. Tim Van Hauwermeiren, CEO & Exec. Director (Age 46)
  • Mr. Eric Castaldi, Chief Financial Officer (Age 54)
  • Prof. Hans de Haard, Chief Scientific Officer (Age 58)
  • Mr. Dirk Marcel Leon Beeusaert, Gen. Counsel (Age 54)
  • Dr. Torsten Dreier, Chief Devel. Officer (Age 54)

When did argenx IPO?

(ARGX) raised $65 million in an initial public offering on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are argenx's major shareholders?

argenx's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (10.80%), Baker BROS. Advisors LP (3.17%), Redmile Group LLC (3.03%), Federated Investors Inc. PA (2.99%), BB Biotech AG (2.28%) and Franklin Resources Inc. (1.87%).

Which institutional investors are selling argenx stock?

ARGX stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, VHCP Management II LLC, Renaissance Technologies LLC, Morgan Stanley, Dorsey Wright & Associates, Tekla Capital Management LLC, QVT Financial LP and AWM Investment Company Inc..

Which institutional investors are buying argenx stock?

ARGX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Redmile Group LLC, BB Biotech AG, Jennison Associates LLC, Laurion Capital Management LP, Federated Investors Inc. PA, Sphera Funds Management LTD. and Franklin Resources Inc..

How do I buy shares of argenx?

Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is argenx's stock price today?

One share of ARGX stock can currently be purchased for approximately $101.96.

How big of a company is argenx?

argenx has a market capitalization of $3.32 billion and generates $44.74 million in revenue each year. The company earns $-31,730,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. argenx employs 73 workers across the globe.

What is argenx's official website?

The official website for argenx is http://www.argenx.com.

How can I contact argenx?

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected]


MarketBeat Community Rating for argenx (NASDAQ ARGX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  530
MarketBeat's community ratings are surveys of what our community members think about argenx and other stocks. Vote "Outperform" if you believe ARGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel